Publications 2021

Aaen KH, Anthi AK, Sandlie I, Nilsen J, Mester S, Andersen JT (2021)
The neonatal Fc receptor in mucosal immune regulation
Scand J Immunol, 93 (2), e13017
DOI 10.1111/sji.13017, PubMed 33351196

Azevedo C, Andersen JT, Traverso G, Sarmento B (2021)
The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs
Eur J Pharm Biopharm, 162, 99-104
DOI 10.1016/j.ejpb.2021.03.009, PubMed 33771621

Azevedo C, Pinto S, Benjakul S, Nilsen J, Santos HA, Traverso G, Andersen JT, Sarmento B (2021)
Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery
Adv Drug Deliv Rev, 175, 113778
DOI 10.1016/j.addr.2021.04.016, PubMed 33887405

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
Ann Intern Med, 174 (9), 1261-1269
DOI 10.7326/M21-0653, PubMed 34251903

Christopoulos PF, Gjølberg TT, Krüger S, Haraldsen G, Andersen JT, Sundlisæter E (2021)
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
Front Immunol, 12, 668207
DOI 10.3389/fimmu.2021.668207, PubMed 33912195

Høydahl LS, Frigstad T, Rasmussen IB, Øynebråten I, Schjetne KW, Andersen JT, Michaelsen TE, Lunde E, Bogen B, Sandlie I (2021)
Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses
Vaccine, 39 (11), 1583-1592
DOI 10.1016/j.vaccine.2021.02.012, PubMed 33612340

Jorstad OK, Sivertsen MS, Andersen JT, Moe MC (2021)
Can the ampoules of covid-19 vaccine be used better?
Tidsskr. Nor. Laegeforen., 141 (2), 110

Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA (2021)
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
Commun Biol, 4 (1), 310
DOI 10.1038/s42003-021-01790-2, PubMed 33686177

Merten H, Brandl F, Zimmermann M, Schaefer JV, Irpinio L, Sand KMK, Nilsen J, Andersen JT, Zangemeister-Wittke U, Plückthun A (2021)
Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling
Eur J Pharm Biopharm, 167, 104-113
DOI 10.1016/j.ejpb.2021.07.011, PubMed 34303832

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
MAbs, 13 (1), 1893888
DOI 10.1080/19420862.2021.1893888, PubMed 33691596

Sivertsen MS, Lode HE, Gjølberg TT, Petrovski G, Andersen JT, Jørstad ØK, Moe MC (2021)
Cluster of symptomatic silicone oil droplets following intravitreal injections: a 1-year observational study
BMJ Open Ophthalmol, 6 (1), e000764
DOI 10.1136/bmjophth-2021-000764, PubMed 34485702

Publications 2020

Azevedo C, Nilsen J, Grevys A, Nunes R, Andersen JT, Sarmento B (2020)
Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin
J Control Release, 327, 161-173
DOI 10.1016/j.jconrel.2020.08.005, PubMed 32771477

Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT (2020)
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
Sci Transl Med, 12 (565)
DOI 10.1126/scitranslmed.abb0580, PubMed 33055243

Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, O'Connell K, Mayes K, Higginson K, Iturriza-Gómara M, Desselberger U, James LC (2020)
Intracellular neutralisation of rotavirus by VP6-specific IgG
PLoS Pathog, 16 (8), e1008732
DOI 10.1371/journal.ppat.1008732, PubMed 32750093

Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538

Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, Grevys A, Foss S, Menzies SC, Glickman JN, Fiebiger E, Roopenian DC, Sandlie I, Andersen JT, Sly LM, Baker K, Blumberg RS (2020)
FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity
J Exp Med, 217 (10)
DOI 10.1084/jem.20200359, PubMed 32658257

Jørstad ØK, Sivertsen MS, Andersen JT, Moe MC (2020)
Can vials of COVID-19 vaccine be used more effectively?
Tidsskr Nor Laegeforen, 140 (2)
DOI 10.4045/tidsskr.20.1039, PubMed 33528143

Lau C, McAdam MB, Bergseth G, Grevys A, Bruun JA, Ludviksen JK, Fure H, Espevik T, Moen A, Andersen JT, Mollnes TE (2020)
NHDL, a recombinant V_L/V_H hybrid antibody control for IgG2/4 antibodies
MAbs, 12 (1), 1686319
DOI 10.1080/19420862.2019.1686319, PubMed 31671278

Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, Roopenian DC, Sandlie I, Rand KD, Andersen JT (2020)
An intact C-terminal end of albumin is required for its long half-life in humans
Commun Biol, 3 (1), 181
DOI 10.1038/s42003-020-0903-7, PubMed 32313072

Publications 2019

Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Lode HE, McAdam MB, Sandlie I, Andersen JT, James LC (2019)
Complement C4 Prevents Viral Infection through Capsid Inactivation
Cell Host Microbe, 25 (4), 617-629.e7
DOI 10.1016/j.chom.2019.02.016, PubMed 30926239

Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT (2019)
TRIM21-From Intracellular Immunity to Therapy
Front Immunol, 10, 2049
DOI 10.3389/fimmu.2019.02049, PubMed 31555278

Labzin LI, Bottermann M, Rodriguez-Silvestre P, Foss S, Andersen JT, Vaysburd M, Clift D, James LC (2019)
Antibody and DNA sensing pathways converge to activate the inflammasome during primary human macrophage infection
EMBO J, 38 (21), e101365
DOI 10.15252/embj.2018101365, PubMed 31468569

Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT (2019)
A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
Sci Rep, 9 (1), 18021
DOI 10.1038/s41598-019-54226-7, PubMed 31792234

Maaland AF, Heyerdahl H, O'Shea A, Eiriksdottir B, Pascal V, Andersen JT, Kolstad A, Dahle J (2019)
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate ¹⁷⁷Lu-NNV003
Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
DOI 10.1007/s00259-019-04417-1, PubMed 31309259

Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019)
The Neonatal Fc Receptor (FcRn): A Misnomer?
Front Immunol, 10, 1540
DOI 10.3389/fimmu.2019.01540, PubMed 31354709

Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
Publisher Correction: Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
Nat Nanotechnol, 14 (4), 398
DOI 10.1038/s41565-019-0404-3, PubMed 30783200

Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
Nat Nanotechnol, 14 (2), 184-190
DOI 10.1038/s41565-018-0336-3, PubMed 30643273

Publications 2018

Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Hirst JC, McAdam MB, Slodkowicz G, Hutchinson E, Kozik P, Andersen JT, James LC (2018)
TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination
Proc Natl Acad Sci U S A, 115 (41), 10440-10445
DOI 10.1073/pnas.1806314115, PubMed 30209217

Grevys A, Nilsen J, Sand KMK, Daba MB, Øynebråten I, Bern M, McAdam MB, Foss S, Schlothauer T, Michaelsen TE, Christianson GJ, Roopenian DC, Blumberg RS, Sandlie I, Andersen JT (2018)
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Nat Commun, 9 (1), 621
DOI 10.1038/s41467-018-03061-x, PubMed 29434196

Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT (2018)
Human and mouse albumin bind their respective neonatal Fc receptors differently
Sci Rep, 8 (1), 14648
DOI 10.1038/s41598-018-32817-0, PubMed 30279529

Nilsen J, Sandlie I, Roopenian DC, Andersen JT (2018)
Animal models for evaluation of albumin-based therapeutics
Curr. Opin. Chem. Eng., 19, 68-76
DOI 10.1016/j.coche.2017.11.007

Sivertsen MS, Jørstad ØK, Grevys A, Foss S, Moe MC, Andersen JT (2018)
Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
Sci Rep, 8 (1), 2101
DOI 10.1038/s41598-018-20525-8, PubMed 29391560

Stapleton NM, Armstrong-Fisher SS, Andersen JT, van der Schoot CE, Porter C, Page KR, Falconer D, de Haas M, Williamson LM, Clark MR, Vidarsson G, Armour KL (2018)
Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport
Mol Immunol, 95, 1-9
DOI 10.1016/j.molimm.2018.01.006, PubMed 29367080

Publications 2017

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2017)
Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity
Sci Rep, 7, 45418
DOI 10.1038/srep45418, PubMed 28382939

Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, Taylor ZS, McDonnell K, Nienaber V, Andersen JT, Mizoguchi A, Blumberg L, Purohit S, Jones SD, Christianson G, Lencer WI, Sandlie I, Kaplowitz N, Roopenian DC, Blumberg RS (2017)
Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury
Proc Natl Acad Sci U S A, 114 (14), E2862-E2871
DOI 10.1073/pnas.1618291114, PubMed 28330995

Publications 2016

Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2016)
Antibody-antigen kinetics constrain intracellular humoral immunity
Sci Rep, 6, 37457
DOI 10.1038/srep37457, PubMed 27881870

Cardoso I, Østerlund EC, Stamnaes J, Iversen R, Andersen JT, Jørgensen TJ, Sollid LM (2016)
Dissecting the interaction between transglutaminase 2 and fibronectin
Amino Acids, 49 (3), 489-500
DOI 10.1007/s00726-016-2296-y, PubMed 27394141

Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Høydahl LS, Dalhus B, Michaelsen TE, Sandlie I, James LC, Andersen JT (2016)
TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity
J Immunol, 196 (8), 3452-3459
DOI 10.4049/jimmunol.1502601, PubMed 26962230

Publications 2015

Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT (2015)
The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
J Control Release, 211, 144-62
DOI 10.1016/j.jconrel.2015.06.006, PubMed 26055641

Cardoso I, Stamnaes J, Andersen JT, Melino G, Iversen R, Sollid LM (2015)
Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies
FEBS J, 282 (11), 2063-75
DOI 10.1111/febs.13276, PubMed 25808416

Chen X, Hnida K, Graewert MA, Andersen JT, Iversen R, Tuukkanen A, Svergun D, Sollid LM (2015)
Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease
J Biol Chem, 290 (35), 21365-75
DOI 10.1074/jbc.M115.669895, PubMed 26160175

Czajkowsky DM, Andersen JT, Fuchs A, Wilson TJ, Mekhaiel D, Colonna M, He J, Shao Z, Mitchell DA, Wu G, Dell A, Haslam S, Lloyd KA, Moore SC, Sandlie I, Blundell PA, Pleass RJ (2015)
Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications
Sci Rep, 5, 9526
DOI 10.1038/srep09526, PubMed 25912958

Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT (2015)
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
J Control Release, 223, 42-52
DOI 10.1016/j.jconrel.2015.12.033, PubMed 26718855

Foss S, Watkinson R, Sandlie I, James LC, Andersen JT (2015)
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity
Immunol Rev, 268 (1), 328-39
DOI 10.1111/imr.12363, PubMed 26497531

Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT (2015)
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
J Immunol, 194 (11), 5497-508
DOI 10.4049/jimmunol.1401218, PubMed 25904551

Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2015)
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
Front Immunol, 5, 682
DOI 10.3389/fimmu.2014.00682, PubMed 25674083

Publications 2014

Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J (2014)
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding
J Biol Chem, 289 (19), 13492-502
DOI 10.1074/jbc.M114.549832, PubMed 24652290

Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispens T, van der Schoot CE, Vidarsson G (2014)
On the perplexingly low rate of transport of IgG2 across the human placenta
PLoS One, 9 (9), e108319
DOI 10.1371/journal.pone.0108319, PubMed 25251461

Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, Christiansen D, Lau C, Brekke OL, Armstrong E, Stefanovic V, Andersen JT, Sandlie I, Mollnes TE (2014)
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
Immunobiology, 220 (4), 452-9
DOI 10.1016/j.imbio.2014.11.003, PubMed 25468724

Rahman MA, Kristiansen PE, Veiseth SV, Andersen JT, Yap KL, Zhou MM, Sandlie I, Thorstensen T, Aalen RB (2014)
The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure
Biochemistry, 53 (13), 2091-100
DOI 10.1021/bi401436h, PubMed 24625295

Sand KM, Bern M, Nilsen J, Dalhus B, Gunnarsen KS, Cameron J, Grevys A, Bunting K, Sandlie I, Andersen JT (2014)
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn)
J Biol Chem, 289 (50), 34583-94
DOI 10.1074/jbc.M114.587675, PubMed 25344603

Sand KM, Dalhus B, Christianson GJ, Bern M, Foss S, Cameron J, Sleep D, Bjørås M, Roopenian DC, Sandlie I, Andersen JT (2014)
Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies
J Biol Chem, 289 (24), 17228-39
DOI 10.1074/jbc.M113.522565, PubMed 24764301

Publications 2013

Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I (2013)
Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics
J Biol Chem, 288 (33), 24277-85
DOI 10.1074/jbc.M113.463000, PubMed 23818524

Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I (2013)
Selection of nanobodies that target human neonatal Fc receptor
Sci Rep, 3, 1118
DOI 10.1038/srep01118, PubMed 23346375

Jacobsen JT, Sundvold-Gjerstad V, Skjeldal FM, Andersen JT, Abrahamsen G, Bakke O, Spurkland A, Bogen B (2013)
B-cell tolerance to the B-cell receptor variable regions
Eur J Immunol, 43 (10), 2577-87
DOI 10.1002/eji.201243203, PubMed 23839948

Lau C, Gunnarsen KS, Høydahl LS, Andersen JT, Berntzen G, Pharo A, Lindstad JK, Ludviksen JK, Brekke OL, Barratt-Due A, Nielsen EW, Stokes CR, Espevik T, Sandlie I, Mollnes TE (2013)
Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation
J Immunol, 191 (9), 4769-77
DOI 10.4049/jimmunol.1301653, PubMed 24062486

Mathiesen L, Nielsen LK, Andersen JT, Grevys A, Sandlie I, Michaelsen TE, Hedegaard M, Knudsen LE, Dziegiel MH (2013)
Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions
Blood, 122 (7), 1174-81
DOI 10.1182/blood-2012-12-473843, PubMed 23843496

Publications 2012

Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjørås M, Sleep D, Sandlie I (2012)
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
Nat Commun, 3, 610
DOI 10.1038/ncomms1607, PubMed 22215085

Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I (2012)
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life
J Biol Chem, 287 (27), 22927-37
DOI 10.1074/jbc.M112.355131, PubMed 22570488

Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, Sarkar CA, Georgiou G (2012)
Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity
ACS Chem Biol, 8 (2), 368-75
DOI 10.1021/cb300455f, PubMed 23030766

Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, Orcutt KD, Wittrup KD, Shively JE, Raubitschek A, Colcher D (2012)
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
Protein Eng Des Sel, 26 (3), 187-93
DOI 10.1093/protein/gzs096, PubMed 23175797

Publications 2011

Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, Sandlie I, Chen Z, de Haar C, Lencer WI, Fiebiger E, Blumberg RS (2011)
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
Proc Natl Acad Sci U S A, 108 (24), 9927-32
DOI 10.1073/pnas.1019037108, PubMed 21628593

Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, McIntosh RS, Sandlie I, He J, Hu J, Shao Z, Pleass RJ (2011)
Polymeric human Fc-fusion proteins with modified effector functions
Sci Rep, 1, 124
DOI 10.1038/srep00124, PubMed 22355641

Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G (2011)
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
Nat Commun, 2, 599
DOI 10.1038/ncomms1608, PubMed 22186895

Publications 2010

Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C (2010)
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
J Biol Chem, 286 (7), 5234-41
DOI 10.1074/jbc.M110.164848, PubMed 21138843

Publications 2009

Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I (2009)
Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding
J Biol Chem, 285 (7), 4826-36
DOI 10.1074/jbc.M109.081828, PubMed 20018855

Andersen JT, Daba MB, Sandlie I (2009)
FcRn binding properties of an abnormal truncated analbuminemic albumin variant
Clin Biochem, 43 (4-5), 367-72
DOI 10.1016/j.clinbiochem.2009.12.001, PubMed 20006594

Andersen JT, Sandlie I (2009)
The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics
Drug Metab Pharmacokinet, 24 (4), 318-32
DOI 10.2133/dmpk.24.318, PubMed 19745559

Publications 2008

Andersen JT (2008)
Expression and ligand binding properties of recombinant soluble neonatal Fc receptor
In Series of dissertations submitted to the Faculty of Mathematics and Natural Sciences, University of Oslo, The Faculty, Oslo, nr. 777, 1 b. (flere pag.)
BIBSYS 082397244

Berntzen G, Andersen JT, Ustgård K, Michaelsen TE, Mousavi SA, Qian JD, Kristiansen PE, Lauvrak V, Sandlie I (2008)
Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation
J Biol Chem, 284 (2), 1126-35
DOI 10.1074/jbc.M803584200, PubMed 18957413

Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS (2008)
Dependence of antibody-mediated presentation of antigen on FcRn
Proc Natl Acad Sci U S A, 105 (27), 9337-42
DOI 10.1073/pnas.0801717105, PubMed 18599440

Publications 2007

Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I (2007)
A strategy for bacterial production of a soluble functional human neonatal Fc receptor
J Immunol Methods, 331 (1-2), 39-49
DOI 10.1016/j.jim.2007.11.003, PubMed 18155020

Andersen JT, Sandlie I (2007)
A receptor-mediated mechanism to support clinical observation of altered albumin variants
Clin Chem, 53 (12), 2216
DOI 10.1373/clinchem.2007.097071, PubMed 18267931

Publications 2006

Andersen JT, Dee Qian J, Sandlie I (2006)
The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin
Eur J Immunol, 36 (11), 3044-51
DOI 10.1002/eji.200636556, PubMed 17048273

Publications 2005

Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I (2005)
Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells
J Immunol Methods, 298 (1-2), 93-104
DOI 10.1016/j.jim.2005.01.002, PubMed 15847800

Publications 2004

Andersen JT (2004)
Cloning and expression of soluble human neonatal receptor
J.T. Andersen, Oslo, 148 s.
BIBSYS 040863808